 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Phase I Systemic Administration Trial - United Kingdom In June 2007, Oncolytics announced that final results of the U.K. Phase I systemic administration trial were being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The results demonstrated that REOLYSIN® was well tolerated by patients with several notable changes in stabilization of disease, as well as some minor tumor regression in patients who had failed all previous treatments. The primary objective of Oncolytics' first systemic administration study was to determine the safety of REOLYSIN® when administered intravenously. The secondary objective was to observe tumour and immune system response to intravenous infusion of REOLYSIN®, which will help to determine dosage levels in subsequent clinical studies. Patients who derived benefit from the therapy were able to be retreated at the same dosage at which they were initially treated. Patients with advanced stage, primary or metastatic solid tumours who had failed all other cancer therapies were enrolled at the Royal Marsden and St. George's Hospital in the United Kingdom See related press releases and documents: June 1, 2007 - Oncolytics Biotech Inc.’s Research Collaborators to Present REOLYSIN® Clinical Trial Data at ASCO Conference November 9, 2006 - Oncolytics Biotech Inc.’s Research Collaborators Present REOLYSIN® Phase I UK Systemic Administration Clinical Trial Results November 7, 2006 - Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Research at 18th EORTC-NCI-AACR Symposium June 5, 2006 - Oncolytics Biotech Inc. Completes Patient Enrolment in UK Phase I Systemic Administration Clinical Trial June 5, 2006 - Oncolytics Biotech Inc.’s Research Collaborators Present Positive REOLYSIN® Clinical Trial Data at ASCO Conference March 16, 2006 - Oncolytics Biotech Inc.’s Research Collaborators to Present REOLYSIN® Clinical Trial Data at ASCO Conference November 17, 2005 - Poster Session C31, "A Phase I study of a wild-type reovirus (Reolysin) given intravenously" Dr. J. de Bono November 14, 2005 - Oncolytics Biotech Inc. to Webcast Clinical Trial Update for REOLYSIN® May 26, 2004 - Oncolytics Biotech Starts Patient Treatment in UK Phase I Cancer Trial Investigating Systemic Delivery of REOLYSIN® February 27 , 2004 - Oncolytics Biotech Receives Approval To Initiate UK Phase I Cancer Trial Investigating Systemic Delivery of REOLYSIN® |
|
|||||||||||
 |
|
 |